RxDoctor Payments Data

Diane Triolo, MD

Nephrology · Wayne, NJNPI 1710166228

Payments from drug & device makers

$914in general payments, 2019–2025

Across 39 payments — averaging $23.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$169
  • Mozarc Medical US LLC$119
  • Vifor Pharma, Inc.$109
  • Novo Nordisk$98
  • AstraZeneca$60
  • Akebia Therapeutics Inc$56
  • plus $303 from 11 others

What the payments were for

  • Food & beverage$83892%
  • Education$768%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$914 in reported general payments places this provider in the 45th percentile of 413 nephrology providers in New Jersey.

See all nephrology providers in New Jersey

Medicare billing

Part B allowed, 2024
$205,919
Medicare patients
348
Services billed
1,489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VeltassaPatiromer Calcium Sorbitex33$31,935
Droxidopa21$24,054
EliquisApixaban27$21,872
RenvelaSevelamer Carbonate12$18,894
JardianceEmpagliflozin13$9,963
Sevelamer Carbonate30$6,438
RetacritEpoetin Alfa-Epbx16$5,409
Breo ElliptaFluticasone/Vilanterol11$4,405
DexilantDexlansoprazole13$3,928
Midodrine Hcl18$1,490
Potassium Citrate ErPotassium Citrate17$1,460
Cinacalcet Hcl14$1,047
Metolazone13$869
Nano 2nd Gen Pen NeedlePen Needle, Diabetic13$821
Allopurinol47$660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta$11$4,40511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 413 nephrology providers in New Jersey.

Other nephrology in Wayne

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →